pharma news today glp-1 obesity Prime Therapeutics' leading research shows only 1 in 12 remain on a drug for at three years Obesity GLP-1 Market Size to

GHK-Cu is generally well tolerated, with fewer reports of scalp irritation

The GLP-1 Analogues market was valued at USD 37 Billion in 2023 and is expected to grow at a CAGR of 28% during the forecast period (2024-2032)

Beyond weight loss, the SELECT trial showed semaglutide reduces major adverse cardiovascular events by 20 percent in patients with obesity and established cardiovascular disease, even without diabetes [Lincoff SELECT, NEJM 2023]

For Muscle Growth and Body Composition Sermorelin offers more significant long-term body composition benefits through sustained GH and IGF-1 elevation

doi: 10.1002/PHAR.4607 45 LiuZBianNWuSFanYLiHYuJet al